Ratio Therapeutics Inc.

About Ratio Therapeutics Inc.

Ratio Therapeutics is a discovery through early clinical phase pharmaceutical company focused on developing best-in-class targeted radiotherapeutics for the treatment of cancers using innovative technologies.

Products & Services

Trillium™ Targeting Scaffold:A proprietary small molecule targeting agent that combines pharmacokinetic modulation with advanced chelation technology to attack a broad array of cancer targets.

Theranostics Platform:A de-risked platform accommodating imaging and therapeutic radioisotopes, with tunable properties and small-scale imaging trials for accelerated compound selection.

Trillium™ targeting scaffold

targeted radiotherapeutics

theranostics compounds

Specialties

Radiopharmaceuticals Cancer Treatment Theranostics Pharmacokinetic Modulation Chelation Technology radiopharmaceuticals PK Modulation technology targeted cancer therapies theranostics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 70000000 MR: - FA: $70M FAN: 70000000	D: 2026-07-31 FD: 2026-07-31	5 investors
2	RT: Series B T: - FT: Series B	A: 50000000 MR: - FA: $50M FAN: 50000000	D: 2024-01-17 FD: 2024-01-17	5 investors
3	RT: Series A T: - FT: Series A	A: 20000000 MR: - FA: $20 million FAN: 20000000	D: 2023-02-01 FD: 2023-02-01	3 investors

Series C Latest

2026-07-31

$70.0M

5 investors (Pro only)

Series B 2024-01-17

$50.0M

Series A 2023-02-01

$20.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News